Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis.
<h4>Objectives</h4>Anti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics.<h4>Methods</h4>We retrospectively analyzed the clinical data of psoriasi...
Main Authors: | Hanae Miyagawa, Hiromichi Hara, Jun Araya, Shunsuke Minagawa, Takanori Numata, Yoshinori Umezawa, Akihiko Asahina, Hidemi Nakagawa, Kazuyoshi Kuwano |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0245284 |
Similar Items
-
Interstitial Pneumonia in Psoriasis
by: Hironori Kawamoto, MD, et al.
Published: (2018-12-01) -
Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study
by: Takanori Numata, et al.
Published: (2020-01-01) -
Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
by: Takanori Numata, et al.
Published: (2020-08-01) -
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
by: Takanori Numata, et al.
Published: (2019-10-01) -
Mitochondrial Quality Control in COPD and IPF
by: Hiromichi Hara, et al.
Published: (2018-07-01)